A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

In conclusion, a demerger, like any major pivot, is a high-stakes, high-value moment where everything matters. Reconnect to ...

The pharmaceutical industry is undergoing a major transformation, placing patients at the forefront of drug development like ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, ...

Many will celebrate having an extra hour in bed – perhaps forgetting how they lost an hour at the end of March when the ...

The increasing complexity of emerging therapies and the need for faster development have led to the adoption of advanced ...

To learn more about the true value of AI and GenAI in pharma, pharmaphorum spoke with Sudip Chakraborty, Principal and Head ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Earlier this month, Sanofi revealed talks were ongoing with CD&R, and has now confirmed the negotiations could result in the ...